PEG-ing down (and preventing?) the cause of pegloticase failure
Division of Rheumatology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030, USA
Arthritis Research & Therapy 2014, 16:112 doi:10.1186/ar4572
See related research by Hershfield et al. http://arthritis-research.com/content/16/2/R63.Published: 30 May 2014
Pegloticase is a powerful but underutilized weapon in the rheumatologist’s armamentarium. The drug’s immunogenicity leads to neutralizing antibody formation and rapid loss of efficacy in roughly one-half of all patients, which remains an impediment to broader use. New data, however, suggest that drug survival might improve with concomitant immunosuppressive agent (s), which merits further study. Efficacy appears to be unchanged when pegloticase is infused at 3-week (rather than 2-week) intervals. Stretching the time between infusions may also improve patient adherence and allow for earlier identification of transient responders.